Results 181 to 190 of about 290,996 (382)

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García, Teresa López‐Sobrino, Esther Sanz‐Girgas, Maria R. Cueto, Jaime Aboal, Pablo Pastor, Irene Buera, Alessandro Sionis, Rut Andrea, Judit Rodríguez‐López, Jose Carlos Sánchez‐Salado, Carlos Tomas, Jordi Bañeras, Albert Ariza, Josep Lupón, Antoni Bayés‐Genís, Ferran Rueda, Grup de Treball de Cures Agudes Cardiològiques Societat Catalana de Cardiologia   +17 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Predicting acute decompensated heart failure using circadian markers from heart rate time series

ESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es, Mayke M. C. J. van Leunen, Ignace L. J. de Lathauwer, Cindy C. A. G. Verstappen, René A. Tio, Ruud F. Spee, Lu Yuan, Monica Betta, Giacomo Handjaras, Hareld M. C. Kemps   +9 more
wiley   +1 more source

Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker.

New England Journal of Medicine, 2015
Vivek Y. Reddy, D. Exner, Daniel J. Cantillon, Rahul N. Doshi, T. Bunch, G. Tomassoni, P. Friedman, N. Estes, J. Ip, I. Niazi, K. Plunkitt, R. Banker, J. Porterfield, J. Ip, Srinivas R. Dukkipati   +14 more
semanticscholar   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

Acute Reduction in Blood Flow in the Right Coronary Artery After PCI Facilitates Pacemaker-Induced Ventricular Fibrillation. [PDF]

Ann Noninvasive Electrocardiol
Wu B, Chen Y, Tang J, He J.
europepmc   +1 more source

Mop3 Is an Essential Component of the Master Circadian Pacemaker in Mammals

Cell, 2000
M. Bunger, Lisa D. Wilsbacher, S. Moran, C. Clendenin, Laurel A. Radcliffe, J. Hogenesch, M. Simon, J. Takahashi, C. Bradfield   +8 more
semanticscholar   +1 more source

Takotsubo cardiomyopathy during armed conflict: A case series

ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha, Artyom Star, Gili Givaty, Michael Shilo, Michael Friger, Vladimir Chitoroga, Hezzy Shmueli, Yigal Abramowitz, Elad Asher, Jamal Jafari, Vladimir Shlyakhover, Doron Zahger, Moti Haim, Chaim Yosefy   +13 more
wiley   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

Outcomes of Supraclavicular Access in Temporary Pacemaker Implantation. [PDF]

Ann Noninvasive Electrocardiol
Yezza AJAB, Hussain M, Butt HMH, Khan QH, Ramani AK, Perveen A, Khan MZ, Abdullah F, Malik J.   +8 more
europepmc   +1 more source